



COLLABORATE FORWARD

November 17, 2020

Meeting Notes: Decentralized Trials Summary of Key Points

Site Implications – PI Oversight

- Industry should focus on training, certification and standardization
- Virtual tools are front and center and have improved with oversight
- Standardization does not need to be MORE complicated than what currently is available
- Identify best telemedicine practices to point to guidelines and templates
- Create work stream with compliance department to improve technology systems
- Understanding the buy-in process with stakeholders

What technology is study specific vs. what should they have in-house?

- Empowering site to utilize technology for the better and for the long term
- Impact of adaptation; determine what the implication is for both the site model and teams
- Technology will enable all stakeholders to be more patient centric

Does reducing patient burden add that burden to the sites?

- Sites have the empowerment to change the patient journey
- Every site is different; continue to change boundaries
- Patient access is challenging; imperative that patient receives best experience possible
- Site have incurred additional costs due to technology; prefer patient provide own device
- Coordinators are having to become IT specialists

Sponsor Implications – When COVID is done, what will stay and what goes back to traditional?

- Currently leveraging what already exists
- Building flexibility in protocols and variety in studies
- Adoption will continue

Staff Implications - Protocol design

- Needs to be resilient and flexible
- Consistent data flow with patient choice being accounted for
- Modernize SCRS working groups with COVID 19
- Regulatory requirements around GDPR will continue to privacy
- KOL Diversity: science logistics
- CRO as advocate of Site KOL